(Q36304331)

13 August 2017

1 reference

title

Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now? (English)

1 reference

13 August 2017

author

Valentín Fuster Carulla

series ordinal

2

1 reference

13 August 2017

Gary Spektor

1

1 reference

13 August 2017

publication date

1 June 2005

1 reference

Nature Clinical Practice Cardiovascular Medicine

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

290-300

1 reference

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cyclo-oxygenase isoenzymes: physiological and pharmacological role

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Clinical pharmacology of platelet cyclooxygenase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Role of prostacyclin in the cardiovascular response to thromboxane A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Nonsteroidal antiinflammatory drugs--differences and similarities

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Mechanism of action of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Cyclooxygenase inhibition and thrombogenicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Cyclooxygenase-2 and inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0214

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0214

1 reference

13 August 2017

1 reference